Oxidative stress and human hypertension: Vascular mechanisms, biomarkers, and novel therapies

Canadian Journal of Cardiology

Volumn 31, Issue 5, 2015, Pages 631-641

  Montezano, Augusto C ^a   Dulak Lis, Maria ^a   Tsiropoulou, Sofia ^a   Harvey, Adam ^a   Briones, Ana M ^b   Touyz, Rhian M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 ACTYLPHENOTHIAZINE; ACETYLCYSTEINE; ALLOPURINOL; ALPHA TOCOPHEROL; APOCYNIN; ASCORBIC ACID; BILIRUBIN; CAROTENOID; CATALASE; CERULOPLASMIN; DIPHENYLENE IODINIUM; FLAVONOID; FULVENE 5; GKT 136901; GKT 137831; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; OXIDOREDUCTASE INHIBITOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 3; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 5; S 17834; SUPEROXIDE DISMUTASE; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG; VAS 2870; VAS 3947; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; XANTHINE OXIDASE;

ANTIOXIDANT ACTIVITY; BLOOD VESSEL INJURY; CARDIOVASCULAR FUNCTION; DNA MODIFICATION; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LIPID PEROXIDATION; METABOLISM; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR BIOLOGY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; FEMALE; LIFESTYLE; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ALLOPURINOL; ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BIOLOGICAL MARKERS; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; FEMALE; HUMANS; HYPERTENSION; LIFE STYLE; MALE; NADPH OXIDASE; OXIDATIVE STRESS; PROGNOSIS; REACTIVE OXYGEN SPECIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; XANTHINE OXIDASE;

EID: 84928786323     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2015.02.008     Document Type: Review

References (120)

1. Sliwa K., Stewart S., Gersh B.J. Hypertension: a global perspective. Circulation 2011, 123:2892-2896.
2. Bauer U.E., Briss P.A., Goodman R.A., Bowman B.A. Prevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USA. Lancet 2014, 384:45-52.
3. Dodhia H., Phillips K., Zannou M.I., Airoldi M., Bevan G. Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population. JHypertens 2012, 30:217-226.
4. Savoia C., Burger D., Nishigaki N., Montezano A., Touyz R.M. Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med 2011, 13:e11.
5. Montezano A.C., Nguyen Dinh Cat A., Rios F.J., Touyz R.M. Angiotensin II and vascular injury. Curr Hypertens Rep 2014, 16:431.
6. Xiao L., Liu Y., Wang N. New paradigms in inflammatory signaling in vascular endothelial cells. Am J Physiol Heart Circ Physiol 2014, 306:H317-H325.
7. Schiffrin E.L. Vascular remodeling in hypertension: mechanisms and treatment. Hypertension 2012, 59:367-374.
8. Xu S., He Y., Vokurkova M., Touyz R.M. Endothelial cells negatively modulate reactive oxygen species generation in vascular smooth muscle cells: role of thioredoxin. Hypertension 2009, 54:427-433.
9. Vukelic S., Griendling K.K. Angiotensin II, from vasoconstrictor to growth factor: a paradigm shift. Circ Res 2014, 114:754-757.
10. Gray S.P., Di Marco E., Okabe J., et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 2013, 127:1888-1902.
11. Nguyen Dinh Cat A., Montezano A.C., Burger D., Touyz R.M. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxid Redox Signal 2013, 19:1110-1120.
12. Dikalov S.I., Ungvari Z. Role of mitochondrial oxidative stress in hypertension. Am J Physiol Heart Circ Physiol 2013, 305:H1417-H1427.
13. Araujo M., Wilcox C.S. Oxidative stress in hypertension: role of the kidney. Antioxid Redox Signal 2014, 20:74-101.
14. Callera G.E., Tostes R.C., Yogi A., Montezano A.C., Touyz R.M. Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms. Clin Sci (Lond) 2006, 110:243-253.
15. Montezano A.C., Touyz R.M. Oxidative stress, Noxs, and hypertension: experimental evidence and clinical controversies. Ann Med 2012, 44:S2-16.
16. Schiffrin E.L. Antioxidants in hypertension and cardiovascular disease. Mol Interv 2010, 10:354-362.
17. Juraschek S.P., Guallar E., Appel L.J., Miller E.R. Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2012, 95:1079-1088.
18. Jones D.P., Radi R. Redox pioneer: professor Helmut Sies. Antioxid Redox Signal 2014, 21:2459-2468.
19. Lushchak V.I. Free radicals, reactive oxygen species, oxidative stress and its classification. Chem Biol Interact 2014, 224C:164-175.
20. Jones D.P. Redefining oxidative stress. Antioxid Redox Signal 2006, 8:1865-1867.
21. Go Y.M., Jones D.P. Redox biology: interface of the exposome with the proteome, epigenome and genome. Redox Biol 2014, 2:358-360.
22. Ray P.D., Huang B.W., Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 2012, 24:981-990.
23. Bretón-Romero R., Lamas S. Hydrogen peroxide signaling in vascular endothelial cells. Redox Biol 2014, 2:529-534.
24. Go Y.M., Jones D.P. Cysteine/cystine redox signaling in cardiovascular disease. Free Radic Biol Med 2011, 50:495-509.
25. Go Y.M., Jones D.P. Thiol/disulfide redox states in signaling and sensing. Crit Rev Biochem Mol Biol 2013, 48:173-181.
26. Jones D.P., Go Y.M. Redox compartmentalization and cellular stress. Diabetes Obes Metab 2010, 12:116-125.
27. Jones D.P. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol 2008, 295:C849-C868.
28. Wei Z., Salmon R.M., Upton P.D., Morrell N.W., Li W. Regulation of bone morphogenetic protein 9 (BMP9) by redox-dependent proteolysis. JBiol Chem 2014, 289:31150-31159.
29. Vikram A., Kim Y.R., Kumar S., et al. Canonical Wnt signaling induces vascular endothelial dysfunction via p66Shc-regulated reactive oxygen species. Arterioscler Thromb Vasc Biol 2014, 34:2301-2309.
30. Spescha R.D., Glanzmann M., Simic B., et al. Adaptor protein p66(Shc) mediates hypertension-associated, cyclic stretch-dependent, endothelial damage. Hypertension 2014, 64:347-353.
31. Tabet F., Schiffrin E.L., Touyz R.M. Mitogen-activated protein kinase activation by hydrogen peroxide is mediated through tyrosine kinase-dependent, protein kinase C-independent pathways in vascular smooth muscle cells: upregulation in spontaneously hypertensive rats. JHypertens 2005, 23:2005-2012.
32. Chatterjee S., Fisher A.B. Mechanotransduction in the endothelium: role of membrane proteins and reactive oxygen species in sensing, transduction, and transmission of the signal with altered blood flow. Antioxid Redox Signal 2014, 20:899-913.
33. Wong W.T., Tian X.Y., Huang Y. Endothelial dysfunction in diabetes and hypertension: cross talk in RAS, BMP4, and ROS-dependent COX-2-derived prostanoids. JCardiovasc Pharmacol 2013, 61:204-214.
34. Hernanz R., Briones A.M., Salaices M., Alonso M.J. New roles for old pathways? A circuitous relationship between reactive oxygen species and cyclo-oxygenase in hypertension. Clin Sci (Lond) 2014, 126:111-121.
35. Martínez-Revelles S., Avendaño M.S., García-Redondo A.B., et al. Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension. Antioxid Redox Signal 2013, 18:51-65.
36. García-Redondo A.B., Briones A.M., Martínez-Revelles S., et al. c-Src, ERK1/2 and Rho kinase mediate hydrogen peroxide-induced vascular contraction in hypertension: role of TXA2, NAD(P)H oxidase and mitochondria. JHypertens 2015, 33:77-87.
37. Spiegelberg B.D. Gprotein coupled-receptor signaling and reversible lysine acetylation. JRecept Signal Transduct Res 2013, 33:261-266.
38. Ushio-Fukai M. Vascular signaling through G protein-coupled receptors: new concepts. Curr Opin Nephrol Hypertens 2009, 18:153-159.
39. Mochin M.T., Underwood K.F., Cooper B., et al. Hyperglycemia and redox status regulate RUNX2 DNA-binding and an angiogenic phenotype in endothelial cells. Microvasc Res 2015, 97:55-64.
40. San Martin A., Griendling K.K. NADPH oxidases: progress and opportunities. Antioxid Redox Signal 2014, 20:2692-2694.
41. Montezano A.C., Touyz R.M. Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research. Antioxid Redox Signal 2014, 20:164-182.
42. Lassegue B., Clempus R.E. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 2003, 285:R277-R297.
43. Konior A., Schramm A., Czesnikiewicz-Guzik M., Guzik T.J. NADPH oxidases in vascular pathology. Antioxid Redox Signal 2014, 20:2794-2814.
44. Schulz E., Wenzel P., Münzel T., Daiber A. Mitochondrial redox signaling: interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid Redox Signal 2014, 20:308-324.
45. Brandes R.P., Weissmann N., Schröder K. Nox family NADPH oxidases: molecular mechanisms of activation. Free Radic Biol Med 2014, 76C:208-226.
46. Laurindo F.R., Araujo T.L., Abrahão T.B. Nox NADPH oxidases and the endoplasmic reticulum. Antioxid Redox Signal 2014, 20:2755-2775.
47. Lambeth J.D., Neish A.S. Nox enzymes and new thinking on reactive oxygen: a double-edged sword revisited. Annu Rev Pathol 2014, 9:119-145.
48. Montezano A.C., Burger D., Ceravolo G.S., et al. Novel Nox homologues in the vasculature: focusing on Nox4 and Nox5. Clin Sci (Lond) 2011, 120:131-141.
49. Montezano A.C., Burger D., Paravicini T.M., et al. Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium/calmodulin-dependent, rac-1-independent pathways in human endothelial cells. Circ Res 2010, 106:1363-1373.
50. Hahn N.E., Meischl C., Kawahara T., et al. NOX5 expression is increased in intramyocardial blood vessels and cardiomyocytes after acute myocardial infarction in humans. Am J Pathol 2012, 180:2222-2229.
51. Touyz R.M., Yao G., Quinn M.T., Pagano P.J., Schiffrin E.L. p47phox associates with the cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H oxidase regulationby angiotensin II. Arterioscler Thromb Vasc Biol 2005, 25:512-518.
52. Touyz R.M., Yao G., Schiffrin E.L. c-Src induces phosphorylation and translocation of p47phox: role in superoxide generation by angiotensin II in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003, 23:981-987.
53. Touyz R.M., Schiffrin E.L. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. JHypertens 2001, 19:1245-1254.
54. Cantu-Medellin N., Kelley E.E. Xanthine oxidoreductase-catalyzed reactive species generation: a process in critical need of reevaluation. Redox Biol 2013, 1:353-358.
55. Berry C.E., Hare J.M. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. JPhysiol 2004, 555:589-606.
56. Riegersperger M., Covic A., Goldsmith D. Allopurinol, uric acid, and oxidative stress in cardiorenal disease. Int Urol Nephrol 2011, 43:441-449.
57. Fukai T., Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal 2011, 15:1583-1606.
58. Qin Z., Reszka K.J., Fukai T., Weintraub N.L. Extracellular superoxide dismutase (ecSOD) in vascular biology: an update on exogenous gene transfer and endogenous regulators of ecSOD. Transl Res 2008, 151:68-78.
59. Maksimenko A.V. Experimental antioxidant biotherapy for protection of the vascular wall by modified forms of superoxide dismutase and catalase. Curr Pharm Des 2005, 11:2007-2016.
60. Hayes J.D., Dinkova-Kostova A.T. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 2014, 39:199-218.
61. Hybertson B.M., Gao B., Bose S.K., McCord J.M. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol Aspects Med 2011, 32:234-246.
62. Howden R. Nrf2 and cardiovascular defense. Oxid Med Cell Longev 2013, 2013:104308.
63. Gomez-Guzman M., Jimenez R., Sanchez M. Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension. Free Rad Biol Med 2012, 52:70-79.
64. Chen J., Zhang Z., Cai L. Diabetic cardiomyopathy and its prevention by nrf2: current status. Diabetes Metab J 2014, 38:337-345.
65. Ahmad A., Singhal U., Hossain M.M., Islam N., Rizvi I. The role of the endogenous antioxidant enzymes and malondialdehyde in essential hypertension. JClin Diagn Res 2013, 7:987-990.
66. Rodrigo R., Libuy M., Feliú F., Hasson D. Oxidative stress-related biomarkers in essential hypertension and ischemia-reperfusion myocardial damage. Dis Markers 2013, 35:773-790.
67. Ward N.C., Hodgson J.M., Puddey I.B. Oxidative stress in human hypertension: association with antihypertensive treatment, gender, nutrition, and lifestyle. Free Radic Biol Med 2004, 36:226-232.
68. Ghasemzadeh N., Patel R.S., Eapen D.J., et al. Oxidative stress is associated with increased pulmonary artery systolic pressure in humans. Hypertension 2014, 63:1270-1275.
69. Carrizzo A., Puca A., Damato A., et al. Resveratrol improves vascular function in patients with hypertension and dyslipidemia by modulating NO metabolism. Hypertension 2013, 62:359-366.
70. Holowatz L.A., Kenney W.L. Local ascorbate administration augments NO- and non-NO-dependent reflex cutaneous vasodilation in hypertensive humans. Am J Physiol Heart Circ Physiol 2007, 293:H1090-H1096.
71. Kurlak L.O., Green A., Loughna P., Broughton Pipkin F. Oxidative stress markers in hypertensive states of pregnancy: preterm and term disease. Front Physiol 2014, 5:310.
72. González J., Valls N., Brito R., Rodrigo R. Essential hypertension and oxidative stress: new insights. World J Cardiol 2014, 6:353-366.
73. Eslami S., Sahebkar A. Glutathione-S-transferase M1 and T1 null genotypes are associated with hypertension risk: a systematic review and meta-analysis of 12 studies. Curr Hypertens Rep 2014, 16:432.
74. Rafiq A., Aslam K., Malik R., Afroze D. C242T polymorphism of the NADPH oxidase p22PHOX gene and its association with endothelial dysfunction in asymptomatic individuals with essential systemic hypertension. Mol Med Rep 2014, 9:1857-1862.
75. Rodrigo R., Prat H., Passalacqua W., et al. Relationship between oxidative stress and essential hypertension. Hypertens Res 2007, 30:1159-1167.
76. Loukogeorgakis S.P., van den Berg M.J., Sofat R., et al. Role of NADPH oxidase in endothelial ischemia/reperfusion injury in humans. Circulation 2010, 121:2310-2316.
77. Sibley C.T., Estwick T., Zavodni A., et al. Assessment of atherosclerosis in chronic granulomatous disease. Circulation 2014, 130:2031-2039.
78. Niki E. Biomarkers of lipid peroxidation in clinical material. Biochim Biophys Acta 2014, 1840:809-817.
79. Lee R., Margaritis M., Channon K.M., Antoniades C. Evaluating oxidative stress in human cardiovascular disease: methodological aspects and considerations. Curr Med Chem 2012, 19:2504-2520.
80. Del Rio D., Stewart A.J., Pellegrini N. Areview of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis 2005, 15:316-328.
81. Bairova T.A., Kolesnikov S.I., Kolesnikova L.I., et al. Lipid peroxidation and mitochondrial superoxide dismutase-2 gene in adolescents with essential hypertension. Bull Exp Biol Med 2014, 158:181-184.
82. Reis G.S., Augusto V.S., Silveira A.P., et al. Oxidative-stress biomarkers in patients with pulmonary hypertension. Pulm Circ 2013, 3:856-861.
83. Petramala L., Pignatelli P., Carnevale R., et al. Oxidative stress in patients affected by primary aldosteronism. JHypertens 2014, 32:2022-2029.
84. Campos C., Guzmán R., López-Fernández E., Casado Á. Urinary biomarkers of oxidative/nitrosative stress in healthy smokers. Inhal Toxicol 2011, 23:148-156.
85. Davies S.S., Roberts L.J. F2-isoprostanes as an indicator and risk factor for coronary heart disease. Free Radic Biol Med 2011, 50:559-566.
86. 2-isoprostanes in inflammation and oxidative stress related pathology. Mol Cells 2010, 30:383-391.
87. Spickett C.M. The lipid peroxidation product 4-hydroxy-2-nonenal: advances in chemistry and analysis. Redox Biol 2013, 1:145-152.
88. Zhang Y., Sano M., Shinmura K., et al. 4-hydroxy-2-nonenal protects against cardiac ischemia-reperfusion injury via the Nrf2-dependent pathway. JMol Cell Cardiol 2010, 49:576-586.
89. Gerardi G., Usberti M., Martini G., et al. Plasma total antioxidant capacity in hemodialyzed patients and its relationships to other biomarkers of oxidative stress and lipid peroxidation. Clin Chem Lab Med 2002, 40:104-110.
90. Fraga C.G., Oteiza P.I., Galleano M. Invitro measurements and interpretation of total antioxidant capacity. Biochim Biophys Acta 2014, 1840:931-934.
91. Pinchuk I., Shoval H., Dotan Y., Lichtenberg D. Evaluation of antioxidants: scope, limitations and relevance of assays. Chem Phys Lipids 2012, 165:638-647.
92. Wang Y., Chun O.K., Song W.O. Plasma and dietary antioxidant status as cardiovascular disease risk factors: a review of human studies. Nutrients 2013, 5:2969-3004.
93. Shacter E. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev 2000, 32:307-326.
94. Jones D.A., Prior S.L., Barry J.D., et al. Changes in markers of oxidative stress and DNA damage in human visceral adipose tissue from subjects with obesity and type 2 diabetes. Diabetes Res Clin Pract 2014, 106:627-633.
95. Baradaran A., Nasri H., Rafieian-Kopaei M. Oxidative stress and hypertension: possibility of hypertension therapy with antioxidants. JRes Med Sci 2014, 19:358-367.
96. Ardalan M.R., Rafieian-Kopaei M. Antioxidant supplementation in hypertension. JRenal Inj Prev 2013, 3:39-40.
97. Drummond G.R., Selemidis S., Griendling K.K., Sobey C.G. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 2011, 10:453-457.
98. Altenhöfer S., Radermacher K.A., Kleikers P.W., Wingler K., Schmidt H.H. Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement. Antioxid Redox Signal 2014, [e-pub ahead of print]. doi: 10.1089/ars.2013.5814, accessed February 26, 2014.
99. Cifuentes-Pagano E., Csanyi G., Pagano P.J. NADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTS. Cell Mol Life Sci 2012, 69:2315-2325.
100. Cifuentes-Pagano E., Meijles D.N., Pagano P.J. The quest for selective nox inhibitors and therapeutics: challenges, triumphs and pitfalls. Antioxid Redox Signal 2014, 20:2741-2754.
101. Ranayhossaini D.J., Rodriguez A.I., Sahoo S., et al. Selective recapitulation of conserved and nonconserved regions of putative NOXA1 protein activation domain confers isoform-specific inhibition of Nox1 oxidase and attenuation of endothelial cell migration. JBiol Chem 2013, 288:36437-36450.
102. Csányi G., Pagano P.J. Strategies aimed at Nox4 oxidase inhibition employing peptides from Nox4 B-Loop and C-terminus and p22 (phox) N-terminus: an elusive target. Int J Hypertens 2013, 2013:842827.
103. Agarwal V., Hans N., Messerli F.H. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. JClin Hypertens (Greenwich) 2013, 15:435-442.
104. Yamagishi S., Ishibashi Y., Ojima A., Sugiura T., Matsui T. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity. Int J Cardiol 2014, 176:550-552.
105. Wang Q., Yang M., Xu H., Yu J. Tetrahydrobiopterin improves endothelial function in cardiovascular disease: a systematic review. Evid Based Complement Alternat Med 2014, 2014:850312.
106. Battelli M.G., Bolognesi A., Polito L. Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. Biochim Biophys Acta 2014, 1842:1502-1517.
107. Higashi Y., Sasaki S., Nakagawa K. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens 2002, 15:326-332.
108. Porkert M., Sher S., Reddy U. Tetrahydrobiopterin: a novel antihypertensive therapy. JHum Hypertens 2008, 22:401-407.
109. Wang Y.Y., Yang Y.X., Zhe H., He Z.X., Zhou S.F. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties. Drug Des Devel Ther 2014, 8:2075-2088.
110. de Zeeuw D., Akizawa T., Audhya P., et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. NEngl J Med 2013, 369:2492-2503.
111. de Zeeuw D., Akizawa T., Agarwal R., et al. Rationale and trial design of Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). Am J Nephrol 2013, 37:212-222.
112. Kweider N., Wruck C.J., Rath W. New insights into the pathogenesis of preeclampsia - the role of Nrf2 activators and their potential therapeutic impact. Geburtshilfe Frauenheilkd 2013, 73:1236-1240.
113. Sánchez-Aranguren L.C., Prada C.E., Riaño-Medina C.E., Lopez M. Endothelial dysfunction and preeclampsia: role of oxidative stress. Front Physiol 2014, 5:372.
114. Fiuza-Luces C., Garatachea N., Berger N.A., Lucia A. Exercise is the real polypill. Physiology (Bethesda) 2013, 28:330-358.
115. Houston M. The role of nutrition and nutraceutical supplements in the treatment of hypertension. World J Cardiol 2014, 6:38-66.
116. Reuland D.J., McCord J.M., Hamilton K.L. The role of Nrf2 in the attenuation of cardiovascular disease. Exerc Sport Sci Rev 2013, 41:162-168.
117. Ghiadoni L., Taddei S., Virdis A. Hypertension and endothelial dysfunction: therapeutic approach. Curr Vasc Pharmacol 2012, 10:42-60.
118. Siervo M., Lara J., Chowdhury S., et al. Effects of the Dietary Approach to Stop Hypertension (DASH) diet on cardiovascular risk factors: a systematic review and meta-analysis. Br J Nutr 2014, 28:1-15.
119. Maxwell S., Greig L. Antioxidants- a protective role in cardiovascular disease?. Expert Opin Pharmacother 2001, 2:1737-1750.
120. Dasgupta K., Padwal R., Poirier L., Quinn R.R. Managing hypertension: evidence supporting the 2013/2014 recommendations of the Canadian Hypertension Education Program. CMAJ 2015, 187:116-119. on behalf of the Canadian Hypertension Education Program Scientific Summary Writing Group.